Seer, Inc. will present extensive research at the 2026 U.S. Human Proteome Organization Annual Conference, demonstrating the clinical applications of its Proteograph Product Suite across multiple disease areas. The company's presentation portfolio, comprising more than a dozen scientific presentations, will highlight the platform's capabilities in cardiovascular disease, neurodegenerative conditions, aging biology, and oncology research.
A centerpiece of Seer's conference participation will be a dedicated breakfast symposium focused on nanoparticle-enabled plasma proteomics technology. This presentation, alongside multiple plenary and poster submissions, is designed to illustrate how the Proteograph platform enables comprehensive protein analysis from minimal sample volumes, a key advancement for clinical research applications.
The presentations underscore the growing role of scalable proteomics in understanding complex disease mechanisms. By enabling detection of thousands of proteins from small-volume samples, the technology addresses a significant challenge in translational research and may facilitate broader adoption of proteomics-based biomarker discovery across therapeutic areas.